Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "ophthalmology"

92 News Found

Nethradhama’s conference on ophthalmology sees launch of advanced eye care technologies
News | January 16, 2024

Nethradhama’s conference on ophthalmology sees launch of advanced eye care technologies

The three-day event in Bengaluru was conducted in collaboration with the Karnataka Ophthalmology Society (KOS) and the Bangalore Ophthalmology Society (BOS)


Alkem forays into ophthalmology with launch of eye care products
News | July 07, 2023

Alkem forays into ophthalmology with launch of eye care products

Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc


GUERISON enters Indian Ophthalmology market
News | February 17, 2023

GUERISON enters Indian Ophthalmology market

The company has launched its new range of 25 allopathy ophthalmic products including GUERIMOD, GUERIPRED, BIMATO MST etc. for curing various diseases related to eyes


Guerison to set up footprints in India’s ophthalmology market
News | December 20, 2022

Guerison to set up footprints in India’s ophthalmology market

Global pharmaceutical company having a surgical business concept incepted in Dubai


SpyGlass Pharma reports promising clinical trial results for glaucoma therapy
Biopharma | November 14, 2025

SpyGlass Pharma reports promising clinical trial results for glaucoma therapy

The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance


Medanta Super Speciality Hospital to set up new hospital in Guwahati
Hospitals | November 02, 2025

Medanta Super Speciality Hospital to set up new hospital in Guwahati

The upcoming state-of-the art 400+ bed facility is set to come up at an approximate cost of Rs 500 crore


Roche presents positive phase III data for vamikibart in uveitic macular edema
Clinical Trials | October 22, 2025

Roche presents positive phase III data for vamikibart in uveitic macular edema

Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME